GWSG
HRTX icon

GPS Wealth Strategies Group’s Heron Therapeutics HRTX Stock Holding History

GPS Wealth Strategies Group’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-72
Closed -$199 – 1380
2024
Q1 		$199 Hold
72
– – ﹤0.01% 1216
2023
Q4 		$122 Hold
72
– – ﹤0.01% 1222
2023
Q3 		$74 Hold
72
– – ﹤0.01% 1262
2023
Q2 		$84 Hold
72
– – ﹤0.01% 1229
2023
Q1 		$109 Buy
+72
New +$180 ﹤0.01% 1230
2022
Q4 		– Sell
-72
Closed – – 551
2022
Q3 		$0 Hold
72
– – ﹤0.01% 1152
2022
Q2 		$0 Hold
72
– – ﹤0.01% 1136
2022
Q1 		$0 Buy
+72
New +$527 ﹤0.01% 1079

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

GPS Wealth Strategies Group's HRTX Position: Q2 2024 in Review

GPS Wealth Strategies Group sold out of Heron Therapeutics (HRTX) in Q2 2024, closing a stake of 72 shares — an estimated $199 sold.

GPS Wealth Strategies Group first reported a position in HRTX in Q1 2022 and held it in 8 quarters. The position peaked at $199 in Q1 2024. 190 funds tracked by Wall St. Rank hold HRTX as of Q2 2024.

  • GPS Wealth Strategies Group reported no remaining Heron Therapeutics position as of Q2 2024 after selling out during the quarter.
  • GPS Wealth Strategies Group sold 72 Heron Therapeutics shares in Q2 2024, an estimated $199.
  • GPS Wealth Strategies Group first reported a position in Heron Therapeutics in Q1 2022 and held it in 8 quarters.
  • GPS Wealth Strategies Group's Heron Therapeutics position peaked at $199 in Q1 2024.
  • 190 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2024.

Based on GPS Wealth Strategies Group's 13F filing for Q2 2024, filed 16 Jul 2024.